Find Reports

Select Report Type

Reimbursement Review

Displaying 501 - 525 of 1258

Please scroll or swipe to the right to view the full content.

Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Dysport Therapeutic	abobotulinumtoxinA	dysport-therapeutic-product-monograph.pdf SR0517_complete_Dysport_Therapeutic_ULS_Oct_26-17_e.pdf SR0517_Dysport_Therapeutic_CL_Report.pdf SR0517_Dysport_Therapeutic_PE_Report.pdf SR0517_Dysport_ULS_PI_Submissions_Consolidated.pdf	Upper limb spasticity	Reimburse with clinical criteria and/or conditions	Complete	Apr 24, 2017	Oct 24, 2017	SR0517-000
Darzalex	Daratumumab	pcodr_profund_10104_daratumumab_darzalex_mm_2ln_beyond.pdf pcodr_daratumumab_darzalex_mm_2ndln_fn_rec.pdf pcodr_daratumumab_darzalex_mm_2ndln_fn_cgr.pdf pcodr_daratumumab_darzalex_mm_2ndln_fn_egr.pdf pcodr_daratumumab_darzalex_mm_2ndln_in_rec.pdf pcodr_daratumumab_darzalex_mm_2ndln_pagfdk.pdf pcodr_daratumumab_darzalex_mm_2ndln_fdk_janssen.pdf pcodr_daratumumab_darzalex_mm_2ndln_ptfdk.pdf pcodr_daratumumab_darzalex_mm_2ndln_clfdk.pdf pcodr_daratumumab_darzalex_mm_2ndln_coi_pt.pdf pcodr_daratumumab_darzalex_mm_2ndln_coi_cl.pdf	Multiple Myeloma (second-line)	Reimburse with clinical criteria and/or conditions	Complete	Mar 3, 2017	Oct 5, 2017	PC0104-000
Lynparza (Resubmission)	Olaparib	pcodr_profund_olaparib_lynparza_resub.pdf pcodr_olaparib_lynparza_resub_fn_rec.pdf pcodr_olaparib_lynparza_resub_fn_cgr.pdf pcodr_olaparib_lynparza_resub_fn_egr.pdf pcodr_olaparib_lynparza_resub_in_rec.pdf pcodr_olaparib_lynparza_resub_pagfdk.pdf pcodr_olaparib_lynparza_resub_fdk_astrazeneca.pdf pcodr_olaparib_lynparza_resub_ptfdk.pdf pcodr_olaparib_lynparza_resub_clinfdk.pdf pcodr_olaparib_lynparza_resub_coi_pt.pdf pcodr_olaparib_lynparza_resub_coi_clin.pdf	Ovarian Cancer	Reimburse with clinical criteria and/or conditions	Complete	Mar 17, 2017	Sep 20, 2017	PC0103-000
Blincyto (Resubmission)	Blinatumomab	pcodr_profund_blinatumomab_blincyto_all_resub.pdf pcodr_blinatumomab_blincyto_all_resub_fn_rec.pdf pcodr_blinatumomab_blincyto_all_resub_fn_cgr.pdf pcodr_blinatumomab_blincyto_all_resub_fn_egr.pdf pcodr_blinatumomab_blincyto_all_resub_in_rec.pdf pcodr_blinatumomab_blincyto_all_resub_pagfdk.pdf pcodr_blinatumomab_blincyto_all_resub_fdk_amgen.pdf pcodr_blinatumomab_blincyto_all_resub_coi_ptgrp.pdf pcodr_blinatumomab_blincyto_all_resub_coi_clinician.pdf	Acute Lymphoblastic Leukemia (ALL)	Reimburse with clinical criteria and/or conditions	Complete	Feb 24, 2017	Aug 31, 2017	PC0097-000
Opdivo	Nivolumab	pcodr_profund_nivolumab_opdivo_scchn.pdf pcodr_nivolumab_opdivo_scchn_fn_rec.pdf pcodr_nivolumab_opdivo_scchn_fn_cgr.pdf pcodr_nivolumab_opdivo_scchn_fn_egr.pdf pcodr_nivolumab_opdivo_scchn_in_rec.pdf pcodr_nivolumab_opdivo_scchn_pagfdk.pdf pcodr_nivolumab_opdivo_scchn_fdk_bms.pdf pcodr_nivolumab_opdivo_scchn_coi_ptgrp.pdf	Squamous Cell Carcinoma of Head and Neck (SCCHN)	Reimburse with clinical criteria and/or conditions	Complete	Jan 31, 2017	Aug 31, 2017	PC0095-000
Rituxan	Rituximab	pcodr_profund_rituximab_rituxan_all.pdf pcodr_rituximab_rituxan_all_fn_rec.pdf pcodr_rituximab_rituxan_all_fn_cgr.pdf pcodr_rituximab_rituxan_all_fn_egr.pdf pcodr_rituximab_rituxan_all_in_rec.pdf pcodr_rituximab_rituxan_all_pagfdk.pdf pcodr_rituximab_rituxan_all_fdk_hlroche.pdf pcodr_rituximab_rituxan_all_coi_clinician.pdf	Acute Lymphoblastic Leukemia	Do not reimburse	Complete	Feb 13, 2017	Aug 31, 2017	PC0102-000
Blincyto	Blinatumomab	pcodr_profund_blinatumomab_blincyto_all_pediatric.pdf pcodr_blinatumomab_blincyto_all_pediatric_fn_rec.pdf pcodr_blinatumomab_blincyto_all_pediatric_fn_cgr.pdf pcodr_blinatumomab_blincyto_all_pediatric_fn_egr.pdf pcodr_blinatumomab_blincyto_all_pediatric_in_rec.pdf pcodr_blinatumomab_blincyto_all_pediatric_pagfdk.pdf pcodr_blinatumomab_blincyto_all_pediatric_fdk_amgen.pdf pcodr_blinatumomab_blincyto_all_pediatric_coi_ptgrp.pdf pcodr_blinatumomab_blincyto_all_pediatric_coi_clinician.pdf	Acute Lymphoblastic Leukemia (pediatric)	Reimburse with clinical criteria and/or conditions	Complete	Feb 24, 2017	Aug 23, 2017	PC0099 -000
Keytruda	Pembrolizumab	PembrolizumabKeytruda_AdvancedNSCLCfirstline10101_ProvFunding.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_rec.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_cgr.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_egr.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_in_rec.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_pagfdk.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fdk_merck.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_coi_ptgrp.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_coi_clinician.pdf	Advanced non-small cell lung carcinoma (first line)	Reimburse with clinical criteria and/or conditions	Complete	Dec 12, 2016	Aug 23, 2017	PC0101-000
Dysport Therapeutic	abobotulinumtoxinA	cdr_SR0512_Dysport_Therapeutic.pdf SR0512_complete_Dysport_Therapeutic_Jul_28_17_e.pdf SR0512_Dysport_Therapeutic_CL_Report_e.pdf SR0512_Dysport_Therapeutic_PE_Report_e.pdf SR0512_Dysport_Therapeutic_PI_Submissions.pdf	Cervical dystonia	Reimburse with clinical criteria and/or conditions	Complete	Jan 31, 2017	Jul 26, 2017	SR0512-000
Cerdelga	Eliglustat	cdr_SR0511_Cerdelga.pdf SR0511_complete_Cerdelga_Jul_28_17_e.pdf SR0511_Cerdelga_CL_Report_e.pdf SR0511_Cerdelga_PE_Report_e.pdf SR0511_Cerdelga_PI_Submissions.pdf	Gaucher disease	Reimburse with clinical criteria and/or conditions	Complete	Jan 20, 2017	Jul 26, 2017	SR0511-000
Erelzi	Etanercept	cdr_SE0513_TBC.pdf SE0513_complete_Erelzi_Jul_28_17_e.pdf SE0513_Erelzi_SEB_Report.pdf SE0513_Erelzi_PI_Submissions.pdf	Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis	Reimburse with clinical criteria and/or conditions	Complete	Feb 2, 2017	Jul 25, 2017	SE0513-000
Ocaliva	Obeticholic Acid	cdr_SR0509_TBC.pdf SR0509_complete_Ocaliva_Jul_27_17_e.pdf SR0509_Ocaliva_CL_Report_e.pdf SR0509_Ocaliva_PE_Report_e.pdf SR0509 Ocaliva_PI_Submissions.pdf	Primary Biliary Cholangitis	Reimburse with clinical criteria and/or conditions	Complete	Dec 22, 2016	Jul 25, 2017	SR0509-000
Glatect	Glatiramer acetate	cdr_SE0510_Glatect.pdf SE0510_complete_Glatect-Jul-27-e.pdf SE0510_Glatect _PI_Submissions.pdf SE0510_Glatect_SENB_Complex_Drug_Submission_Report.pdf	Relapsing Remitting Multiple Sclerosis (RRMS)	Reimburse with clinical criteria and/or conditions	Complete	Jan 20, 2017	Jul 25, 2017	SE0510-000
Ninlaro	Ixazomib	pcodr_provfund_ixazomib_ninlaro_mm.pdf pcodr_ixazomib_ninlaro_mm_fn_rec.pdf pcodr_ixazomib_ninlaro_mm_fn_cgr.pdf pcodr_ixazomib_ninlaro_mm_fn_egr.pdf pcodr_ixazomib_ninlaro_mm_in_rec.pdf pcodr_ixazomib_ninlaro_mm_pagfdk.pdf pcodr_ixazomib_ninlaro_mm_fdk_takeda.pdf pcodr_ixazomib_ninlaro_mm_ptfdk.pdf pcodr_ixazomib_ninlaro_mm_clnfdk.pdf pcodr_ixazomib_ninlaro_mm_coi_mmc.pdf pcodr_ixazomib_ninlaro_mm_coi_cln.pdf	Multiple Myeloma	Do not reimburse	Complete	Dec 16, 2016	Jun 29, 2017	PC0088-000
Zinbryta	Daclizumab beta	cdr_SR0508_Zinbryta.pdf SR0508_compelte_Zinbryta_Jun-22-17_e.pdf SR0508_Zinbryta_CL_Report.pdf SR0508_Zinbryta_PE_Report.pdf SR0508_Zinbryta_PI_Submissions.pdf	Multiple Sclerosis, relapsing-remitting	Reimburse with clinical criteria and/or conditions	Complete	Dec 20, 2016	Jun 20, 2017	SR0508-000
Gazyva	Obinutuzumab	pcodr_profund_obinutuzumab_gazyva_fl.pdf pcodr_obinutuzumab_gazyva_fl_fn_rec.pdf media:document:b525feb5-dfab-4fab-9329-39565d03e75a media:document:e96c2560-fd09-4813-ac09-a3cef1e32514 pcodr_obinutuzumab_gazyva_fl_fn_cgr.pdf pcodr_obinutuzumab_gazyva_fl_fn_egr.pdf pcodr_obinutuzumab_gazyva_fl_in_rec.pdf pcodr_obinutuzumab_gazyva_fl_pagfdk.pdf pcodr_obinutuzumab_gazyva_fl_fdk_roche.pdf pcodr_obinutuzumab_gazyva_fl_ptfdk.pdf pcodr_obinutuzumab_gazyva_fl_coi_pt.pdf	Follicular Lymphoma	Reimburse with clinical criteria and/or conditions	Complete	Nov 4, 2016	Jun 2, 2017	PC0091-000
Lixiana VTE	Edoxaban	cdr_SR0499_Lixiana_VTE.pdf SR0499_complete_Lixiana_VTE_May_29_17_e.pdf SR0499_Lixiana_VTE_CL_Report.pdf SR0499_Lixiana_VTE_PE_Report.pdf	Venous thromboembolism, treatment and recurrence prevention.	Reimburse with clinical criteria and/or conditions	Complete	Sep 9, 2016	May 25, 2017	SR0499-000
Odefsey	emtricitabine/rilpivirine/ tenofovir alafenamide	cdr_SR0507_TBC.pdf SR0507_complete_Odefsey- May-25-17_e.pdf SR0507_Odefsey_Combined_Report.pdf SR0507_Odefsey_PI_Submissions.pdf	HIV-1 infection	Reimburse with clinical criteria and/or conditions	Complete	Nov 24, 2016	May 25, 2017	SR0507-000
Lancora	Ivabradine	cdr_SR0506_Lancora.pdf SR0506_complete_Lancora-Jun15-17_e.pdf SR0506_ Lancora_CL_Report.pdf SR0506_ Lancora_PE_Report.pdf SR0506_Lancora_PI_Submissions.pdf	Heart failure, NYHA class II or III	Reimburse with clinical criteria and/or conditions	Complete	Nov 8, 2016	May 24, 2017	SR0506-000
Tagrisso	Osimertinib	pcodr_provfund_10076_osimertinib_tagrisso_nsclc.pdf pcodr_osimertinib_tagrisso_nsclc_fn_rec.pdf pcodr_osimertinib_tagrisso_nsclc_fn_cgr.pdf pcodr_osimertinib_tagrisso_nsclc_fn_egr.pdf pcodr_osimertinib_tagrisso_nsclc_in_rec.pdf pcodr_osimertinib_tagrisso_nsclc_pagfdk.pdf pcodr_osimertinib_tagrisso_nsclc_fdk_azc.pdf pcodr_osimertinib_tagrisso_nsclc_ptfdk.pdf pcodr_osimertinib_tagrisso_nsclc_clnfdk.pdf pcodr_osimertinib_tagrisso_nsclc_coi_pt.pdf pcodr_osimertinib_tagrisso_nsclc_coi_cln.pdf	Non-Small Cell Lung Cancer	Reimburse with clinical criteria and/or conditions	Complete	Apr 1, 2016	May 4, 2017	PC0076-000
Alecensaro	Alectinib	pcodr_provfund_alectinib_alecensaro_nsclc.pdf pcodr_alectinib_alecensaro_nsclc_fn_rec.pdf pcodr_alectinib_alecensaro_nsclc_fn_cgr.pdf pcodr_alectinib_alecensaro_nsclc_fn_egr.pdf pcodr_alectinib_alecensaro_nsclc_in_rec.pdf pcodr_alectinib_alecensaro_nsclc_pagfdk.pdf pcodr_alectinib_alecensaro_nsclc_fdk_roche.pdf pcodr_alectinib_alecensaro_nsclc_ptfdk.pdf pcodr_alectinib_alecensaro_nsclc_clnfdk.pdf pcodr_alectinib_alecensaro_nsclc_coi_pt.pdf pcodr_alectinib_alecensaro_nsclc_coi_cln.pdf	Non-Small Cell Lung Cancer	Do not reimburse	Complete	Oct 3, 2016	May 4, 2017	PC0092-000
Mictoryl	Propiverine hydrochloride	cdr_SR0504_Mictoryl.pdf SR0504_Mictoryl_CL Report.pdf SR0504_Mictoryl_PE_Report.pdf SR0504_Mictoryl_PI_Submissions.pdf SR0504_complete_Mictoryl_Apr-21-17-e.pdf	Overactive bladder (OAB)	Reimburse with clinical criteria and/or conditions	Complete	Oct 14, 2016	Apr 19, 2017	SR0504-000
Mifegymiso	Mifepristone and misoprostol	cdr_SR0502_Mifegymiso.pdf SR0502_complete_Mifegymiso-Apr-20-17-e.pdf SR0502_Mifegymiso_CL_Report.pdf SR0502_Mifegymiso_PE_Report.pdf	Medical termination of pregnancy (gestational age up to 49 days)	Reimburse	Complete	Oct 7, 2016	Apr 18, 2017	SR0502-000
Kevzara	sarilumab	cdr_SR0503_TBC.pdf SR0503_Kevzara_CL_Report.pdf SR0503_Kevzara_PE_Report.pdf SR0503_Kevzara_PI_Submissions.pdf SR0503_complete_Kevzara-Apr-20-17.pdf	Arthritis, Rheumatoid	Reimburse with clinical criteria and/or conditions	Complete	Oct 12, 2016	Apr 18, 2017	SR0503-000
Caprelsa	Vandetanib	pcodr_provfund_vandetanib_caprelsa_mtc.pdf pcodr_vandetanib_caprelsa_mtc_fn_rec.pdf pcodr_vandetanib_caprelsa_mtc_fn_cgr.pdf pcodr_vandetanib_caprelsa_mtc_fn_egr.pdf pcodr_vandetanib_caprelsa_mtc_in_rec.pdf pcodr_vandetanib_caprelsa_mtc_pagfdk.pdf pcodr_vandetanib_caprelsa_mtc_fdk_sanofig.pdf pcodr_vandetanib_caprelsa_mtc_ptfdk_tcc.pdf pcodr_vandetanib_caprelsa_mtc_coi_tcc.pdf pcodr_vandetanib_caprelsa_mtc_coi_cln.pdf	Medullary Thyroid Cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 15, 2016	Mar 30, 2017	PC0090-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 501 - 525 of 589

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Assessment of Dehydration and Oral Rehydration Therapy for Pediatric Patients with Dehydration: A Review of Clinical Effectiveness, Clinical Utility, and Guidelines	RC1240 ORT diagnosis treatment Final.pdf	Mar 23, 2020	Summary with Critical Appraisal	Completed	RC1240-000
Propranolol for Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness	RC1254 Propranolol PTSD Final.pdf	Mar 23, 2020	Summary with Critical Appraisal	Completed	RC1254-000
The Use of Real-World Evidence for Medical Device Assessment: An Environmental Scan		Mar 19, 2020			ES0344-000
Experiences with and Expectations of Robotic Surgical Systems: A Rapid Qualitative Review	RC1251 RSS for Gyno Uro Surgery Final.pdf	Mar 19, 2020	Summary with Critical Appraisal	Completed	RC1251-000
The Use of Real-World Evidence for Medical Device Assessment ─ An Environmental Scan		Mar 19, 2020			ES0344-000
Identification of Tuberculosis: A Review of the Guidelines	RC1236 TB identification Final.pdf	Mar 18, 2020	Summary with Critical Appraisal	Completed	RC1236-000
Drug-Resistant Tuberculosis: A Review of the Guidelines	RC1239 DR-TB guidelines Final.pdf	Mar 18, 2020	Summary with Critical Appraisal	Completed	RC1239-000
Treatment of Tuberculosis: A Review of Guidelines	RC1237 TB treatment guidelines Final.pdf	Mar 18, 2020	Summary with Critical Appraisal	Completed	RC1237-000
Tuberculosis in People with Compromised Immunity: A Review of Guidelines	RC1238 TB immunocompromised Final.pdf	Mar 18, 2020	Summary with Critical Appraisal	Completed	RC1238-000
Prevention of Tuberculosis: A Review of Guidelines	RC1223 TB prevention guidelines Final.pdf	Mar 18, 2020	Summary with Critical Appraisal	Completed	RC1223-000
Oral Rehydration Solutions versus Drink of Choice in Children with Dehydration: A Review of Clinical Effectiveness	RC1241 ORS Final.pdf	Mar 9, 2020	Summary with Critical Appraisal	Completed	RC1241-000
Local Anesthetic for Urinary Catheter Insertion: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1250 Urinary Catheter Anaesthetic Final.pdf	Mar 9, 2020	Summary with Critical Appraisal	Completed	RC1250-000
Botulinum Toxin for Temporomandibular Disorders: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1245 Botox for TMD Final.pdf	Mar 2, 2020	Summary with Critical Appraisal	Completed	RC1245-000
Manual Therapy for Persistent, Non-Cancer Back and Neck Pain: A Review of Clinical Effectiveness	RC1231 Manual Therapy Neck Back Final.pdf	Mar 2, 2020	Summary with Critical Appraisal	Completed	RC1231-000
Non-pharmacological and Pharmacological Intervention for Smoking Cessation Programs in Youth: A Review of Clinical Effectiveness and Guidelines	RC1235 Smoking Cessation Youth Final.pdf	Mar 2, 2020	Summary with Critical Appraisal	Completed	RC1235-000
Orthotic Bracing or Splinting of Upper Extremities in Patients with Chronic, Non-Cancer Pain: A Review of Clinical Effectiveness	RC1252 Splinting for Upper Extremity Pain Final.pdf	Mar 2, 2020	Summary with Critical Appraisal	Completed	RC1252-000
Magnetic Localization System for Sentinel Lymph Node Biopsy: A Review of the Diagnostic Accuracy, Cost-Effectiveness, and Guidelines	RC1249 Magtrace Final.pdf	Mar 2, 2020	Summary with Critical Appraisal	Completed	RC1249-000
Prenatal and Postnatal Home Visiting Programs for Parents, Newborns, and Babies: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1243 Home Visit Programs Final.pdf	Feb 26, 2020	Summary with Critical Appraisal	Completed	RC1243-000
Lurasidone Hydrochloride for Bipolar Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1244 Lurasidone for BD Final.pdf	Feb 26, 2020	Summary with Critical Appraisal	Completed	RC1244-000
Pilocarpine for Xerostomia and Xerophthalmia in Sjögren’s Syndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1227- Pilocarpine for SIX Final.pdf	Feb 26, 2020	Summary with Critical Appraisal	Completed	RC1227-000
Palivizumab For Infection Prevention in Inuit Infants: A Review of the Clinical Effectiveness and Cost-Effectiveness	RC1217 Palivizumab Prophylaxis Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1217-000
Ondansetron and Oral Rehydration Therapy in Pediatric Patients with Dehydration: Clinical Effectiveness	RC1242 ondansetron Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1242-000
Prostaglandin Analogues for Ophthalmic Use: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1248 Pros Analogues Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1248-000
Quetiapine for Major Depressive Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1233 Quetiapine for MDD Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1233-000
Combination Use of Ivabradine with Sacubitril/Valsartan: A Review of Clinical Effectiveness and Guidelines	RC1247 Ivabradine Sacubitril Valsartan Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1247-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 111 of 111

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 501 - 525 of 2093

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Optimizing the Use of Iodinated Contrast Media: Conservation Strategies Used Across Canada During the 2022 Shortage		CM0001-ICM-Conservation-Strategies.pdf	Sep 20, 2023	Health Technology Review	CMII Service	Completed	CM0001-000
Direct-Acting Antivirals for Pediatric Chronic Hepatitis C Virus Infection		Direct-Acting Antivirals for Pediatric Chronic Hepatitis C Virus Infection	Sep 20, 2023	Health Technology Review	Rapid Review	Completed	RC1502-000
Midline and Extended Dwell Catheters for IV Antibiotics		Midline and Extended Dwell Catheters for IV Antibiotics	Sep 18, 2023	Health Technology Review	Rapid Review	Completed	RC1505-000
Non-Sterile Glove Use		Non-Sterile Glove Use	Sep 15, 2023	Health Technology Review	Rapid Review	Completed	RC1499-000
Somatropin for Short Stature		Somatropin for Short Stature	Sep 15, 2023	Health Technology Review	Rapid Review	Completed	RC1501-000
trastuzumab deruxtecan		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Sep 15, 2023	Reimbursement Review		Complete	PC0305-000
Remdesivir (Veklury) for the Treatment of COVID-19 in the Inpatient Setting		Summary Report — September 2023 Systematic Review — September 2023	Sep 13, 2023	Health Technology Review	Systematic Review	Completed	RE0048-000
Tocilizumab (Actemra) for the Treatment of Hospitalized Patients With COVID-19		Systematic Review — September 2023 Summary Report — September 2023	Sep 13, 2023	Health Technology Review	Systematic Review	Completed	RE0049-000
Nirmatrelvir-Ritonavir (Paxlovid) for the Treatment of COVID-19		Systematic Review, September 2023 Summary Report, September 2023	Sep 12, 2023	Health Technology Review	Health Technology Assessment	Completed	HT0042-000
Remdesivir (Veklury) for the Treatment of COVID-19 in the Outpatient Setting		Systematic Review — September 2023 Summary Report — September 2023	Sep 12, 2023	Health Technology Review	Health Technology Assessment	Completed	HT0041-000
abiraterone acetate and prednisolone		Recommendation and Reasons Stakeholder Input Stakeholder Feedback on Draft Recommendation Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report	Sep 11, 2023	Reimbursement Review		Complete	PX0291-000 - PC0291-000
dapagliflozin		Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input Stakeholder Feedback on Draft Recommendation	Sep 8, 2023	Reimbursement Review		Complete	SX0749-000 - SR0749-000
abiraterone, prednisone, docetaxel		Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input Stakeholder Feedback on Draft Recommendation	Sep 8, 2023	Reimbursement Review		Complete	PX0298-000 - PC0298-000
Timing of Ventilator Circuit Tubing Replacement		Timing of Ventilator Circuit Tubing Replacement	Sep 8, 2023	Health Technology Review	Rapid Review	Completed	RC1498-000
Telephone Triage Services	Telephone triage programs provide timely access to trained health care professionals who can assess a patient’s symptoms over the phone and provide self-care advice or referral to an appropriate level of care.	canadian_telephone_triage_programs_infographic.pdf Telephone Triage Services	Sep 7, 2023	Health Technology Review	Environmental Scan	Completed	ES0378-000
Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)		Implementation Advice	Aug 30, 2023	Health Technology Review	Technology Review	Completed	HC0060-000
vericiguat		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Aug 30, 2023	Reimbursement Review		Complete	SR0758-000
atogepant		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Aug 30, 2023	Reimbursement Review		Complete	SR0724-000
upadacitinib		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Aug 28, 2023	Reimbursement Review		Complete	SR0759-000
Issues in Pediatric Health Care	Shortage events, the phenomena when demand exceeds supply, can affect both medical care and medical devices. The COVID-19 pandemic caused a global shortage event, the consequences of which are still being experienced beyond the peak of the pandemic (e.g., the lack of pediatric pain medication available in fall 2022).	Issues in Pediatric Health Care	Aug 25, 2023	Horizon Scan	Emerging Health Technologies	Completed	EH0116-000
Transcatheter Edge-To-Edge Valve Repair for Tricuspid Regurgitation		Transcatheter Edge-To-Edge Valve Repair for Tricuspid Regurgitation	Aug 22, 2023	Health Technology Review	Rapid Review	Completed	RC1500-000
Artificial Intelligence in Prehospital Emergency Health Care	Health care systems in Canada, including prehospital emergency health care services, are facing staffing shortages and increased patient volumes, and are looking for creative solutions to ensure the provision of high-quality care.	Artificial Intelligence in Prehospital Emergency Health Care	Aug 18, 2023	Horizon Scan	Health Technology Update	Completed	EN0052-000
Utilization of Opioid Agonist Therapies in Canada		Utilization of Opioid Agonist Therapies in Canada	Aug 15, 2023	Health Technology Review	Technology Review	Completed	HC0064-000
cariprazine		Memorandum report to CADTH Response to the Procedural Review Panel’s Memorandum Report on the Procedural R…Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Aug 10, 2023	Reimbursement Review		Complete	SR0708-000
Non-Small Cell Lung Cancer without actionable oncogenic alterations		Final Report	Aug 10, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0029-000